Screener
Corcept Therapeutics CORT Free cash flow
Free cash flow at other companies
Other financials
Where this comes from
Calculated from Corcept Therapeutics’s reported figures.
The source filing: Corcept Therapeutics’s 10-Q, filed July 29, 2026. Open the filing →
- Filed
- Jul 29, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050613
FAQ
- What is Corcept Therapeutics's free cash flow?
- Corcept Therapeutics (CORT) reported free cash flow of $31.02M in Q2 2026.
- How has Corcept Therapeutics's free cash flow changed year-over-year?
- Corcept Therapeutics's free cash flow decreased by 29.3% year-over-year, from $43.88M to $31.02M.
- What is the long-term trend for Corcept Therapeutics's free cash flow?
- Over 4 years (2021 to 2025), Corcept Therapeutics's free cash flow has grown at a -4.1% compound annual growth rate (CAGR), from $167.42M to $141.79M.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.
Ask your AI about Corcept Therapeutics's free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude